The distribution deal follows the Mexican regulatory approval for Sucanon that contains natural ingredients as an OTC treatment for Type-II diabetes.
With a possibility to continue further, the agreement is spanned for 50 years and expects first shipment in June 2013.
PharmaRoth CEO Luis Lopez said the partner will ensure market access and commercial success of Sucanon.
"This agreement is a major milestone for PharmaRoth, and a clear recognition of the demand Sucanon brings," Lopez added.
Sucanon and other insulin sensitizers were shown in pre-clinical and clinical studies to increase the muscle, fat and liver’s sensitivity to the self produced insulin thereby lowering a patient’s blood sugar.